Displaying results 1 - 2 of 2
Clear search
Axol Bioscience collaborates with StrataStem to deliver stem cell based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Together, an extensive panel of consented patient samples and iPSC technology will advance AD drug development and patient stratification.
Axol Bioscience introduces CiPA-validated human stem cell-derived ventricular cardiomyocytes to help improve drug discovery
Cambridge and Edinburgh, UK - Axol Bioscience Ltd., an established provider of iPSC-derived cells, media, and characterization services for life science discovery, announces that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for…